Atlas Trials

Transformed Lymphoma

14 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Transformed Lymphoma

RecordFirmDate
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia (NCT05281809)John Lister2022-04-19
DALY II USA/ MB-CART2019.1 for DLBCL (NCT04792489)Miltenyi Biomedicine GmbH2021-05-25
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL (NCT04796857)Huiqiang Huang2021-03-31
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (NCT04545762)C. Babis Andreadis2020-09-11
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL (NCT04476459)Huiqiang Huang2020-07-23
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma (NCT04058470)Huiqiang Huang2020-04-24
Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes (NCT04319237)H. Lee Moffitt Cancer Center and Research Institute2020-03-10
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma (NCT03837873)Institute of Hematology & Blood Diseases Hospital, China2019-01-21
Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma (NCT04067414)Institute of Hematology & Blood Diseases Hospital, China2018-06-08
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation (NCT03133221)University of Maryland, Baltimore2017-10-23
Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma (NCT00225212)Stanford University1997-11-01

Track Transformed Lymphoma automatically

Every clearance here is in the API, with alerts when new ones post.